Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1046 monotherapy and combination therapy in relapsed/refractory metastatic non-small cell lung cancer after prior immune checkpoint inhibitor treatment
2021-001928-17Phase 2Active
- Sponsor
- Genmab
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing GEN1046 monotherapy with GEN1046 + Keytruda (2 arms). Primary endpoint: Objective response rate. Started Jul 2021; status: active.
02
Drugs
acasunlimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-001928-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001928-17.